Doctors Hospital Health System

Doctors Hospital is a good business wrapped around a single, decisive assumption. It is the only major private hospital system in the Bahamas, demand is defensive, and it has genuine pricing power as the premium option. None of that is the question. The question is what country risk premium belongs in the discount rate, because on that one input the entire valuation turns. To a global investor charging the full 5.13% premium, a discounted cash flow puts fair value near $2.84 against a $4.87 price, about 42% below the market. To a domestic investor charging none, it is about $5.91, roughly 21% above.

The price sits between the two, and that is the useful way to read it. At $4.87 the market is charging a country risk premium of only about 1.4%, roughly a quarter of what a global allocator would demand, pricing Doctors Hospital as if the one-to-one US-dollar peg erases most Bahamian risk. So this note is really an argument about one number, and whether a small fraction of the full premium or the whole of it is the honest price of Bahamas risk.

IThe business

Doctors Hospital Health System (BISX: DHS) is the leading private hospital operator in the Bahamas. Its demand is defensive and non-cyclical, people need care regardless of the economy, and as the premium private provider it holds real pricing power. The business runs in three segments. The core Doctors Hospital (DHB) is about 92% of revenue. BMC is a COVID-era outpatient operation that is now shrinking. KCL, a kidney-care and dialysis business acquired in 2024, is small (~7%) but growing. As BMC fades and DHB and KCL grow, the segments partly offset one another, leaving low-single-digit organic growth roughly in line with population and healthcare inflation.

The operating-leverage bet

The company has about $54M of construction in progress, including a new 25-bed hospital in Grand Bahama and an Eastern New Providence build. The case management is making is operating leverage. The staff and fixed costs are largely already on the books, so as new beds fill, revenue should outgrow costs and margins should expand. The swing factor is salaries. I taper salaries from about 45% of revenue back toward 43% (the pre-FY25 norm was closer to 40%, and FY25 spiked on the KCL integration and pre-opening hiring). If that staffing leverage does not materialise, the value falls hard.

FY25 was a trough

FY25 was a small net loss of about $0.9M, dragged down by pre-opening costs and the KCL integration. The first half of FY26 already swung to a $3.5M profit, so I treat FY25 as a trough rather than a trend. The split-adjusted FY22 price was about $4.28 against $4.87 today, so the stock trades higher than it did in its best year despite weaker recent results.

IIWhere the value sits

This is not really a debate about the hospital. It is a debate about the discount rate, and specifically how much Bahamian country risk to charge. The two lenses bracket the answer, and the market's price reveals which one it leans toward.

1. Expensive to a global investor, cheap to a domestic one. At a full 5.13% premium, fair value is about $2.84 versus $4.87, roughly 42% downside. Strip the premium out, as a domestic buyer does, and fair value is about $5.91, roughly 21% upside. Same cash flows, two required returns.
2. The market charges only a fraction of the full premium. To arrive at $4.87 from these cash flows, the implied country risk premium is about 1.4%, roughly a quarter of the 5.13% a global allocator would demand, as if the US-dollar peg removes most Bahamian sovereign and currency risk. That is the market's real assumption, whether stated or not.
3. The turnaround is why the domestic case works. Crediting the recovery from the FY25 trough and the operating-leverage story, a domestic investor charging little or no premium can reasonably see upside. A global investor pricing full Bahamas risk cannot. Both are looking at the same hospital.

The question was never whether Doctors Hospital is a good business. It is how much Bahamian country risk belongs in the price, and the two lenses put fair value on opposite sides of the tape.

IIIValuation

I value Doctors Hospital with a bottom-up discounted cash flow, explicit unlevered free cash flow discounted at its weighted-average cost of capital, with a Gordon-growth terminal value. The WACC blends the cost of equity with an after-tax cost of debt across a capital structure that is roughly 74% equity and 26% debt. I run it through two lenses. The global lens builds the cost of equity from a US risk-free rate plus the full Bahamas country risk premium. The domestic lens starts from a Bahamas government bond and charges no country premium, the return a local investor barred from freely investing abroad actually faces. As the thesis argues, the country risk premium inside that rate is the single most consequential input.

The two lenses share identical cash flows and a 2.0% terminal growth rate, with salaries tapering from 45% to 43% of revenue as new capacity fills. At a global WACC of about 11.7%, carrying the full country risk premium, fair value is about $2.84, roughly 42% below the price. At the domestic WACC of about 7.7%, with no country premium, it is about $5.91, roughly 21% above, so the price sits between the two lenses. The full model, with every assumption, is available to download.

What moves the value

Two things dominate. First, the country risk premium. At a full 5.13% it produces $2.84, at zero it produces $5.91, and the $4.87 price sits about a third of the way down from the domestic value, implying a premium of only about 1.4%. Second, salary leverage. If salaries do not taper toward 43% of revenue as new capacity fills, margins stall and both fair values fall. Revenue growth and terminal growth matter, but neither rivals these two.

The honest cross-check here is not another model. It is the implied country risk premium. Backing into the rate that justifies $4.87 gives about 1.4%, and stating that plainly is more useful than any multiple. The market is making a specific claim about Bahamian risk, roughly a quarter of the full premium, and where you land on that claim decides whether the stock is cheap or dear.

IVWhat could break it

1. The peg may justify a low country risk premium. The strongest counter is the market's own. If the one-to-one US-dollar peg truly removes most Bahamian currency and sovereign risk, a sub-1.5% premium could be defensible, and the stock is not expensive.
2. Operating leverage could exceed the model. If the new Grand Bahama and New Providence capacity fills faster than assumed and salaries fall back toward 40% of revenue, earnings and fair value rise materially.
3. Defensive, scarce, and improving. A monopoly-like private hospital coming out of a trough is exactly the kind of asset local investors will pay up for, and the premium can persist.
4. Country risk and liquidity. As with every BISX name, the analysis carries a full country risk premium and trades in a thin local market.

VThe model